Orchid Pharma Q3 FY26 Results: Sales ₹207 Cr, EBITDA ₹13 Cr, PBT -₹6 Cr
Orchid Pharma reported Q3 FY26 standalone results with sales at ₹207 crore, down 5% YoY. EBITDA declined 65% to ₹13 crore, and PBT was -₹6 crore. For 9M FY26, sales were ₹574 crore, down 16% YoY, with EBITDA at ₹58 crore and PBT at ₹15 crore. An investor presentation was shared on February 11, 2026.
The decline in key financial metrics like sales and profitability could impact investor sentiment and the company's stock performance, warranting a medium impact assessment.
The company's financial performance for Q3 FY26 shows a significant decline in sales, EBITDA, and PBT compared to the previous year, indicating a negative trend.
Orchid Pharma Limited has released its investor presentation detailing the financial performance for the Quarter-III ended on December 31, 2025. The company reported standalone results, with sales amounting to ₹207 crore, a 5% decrease from ₹217 crore in the same quarter of the previous year (Q3-25).
For the nine-month period ending December 31, 2025 (9M-26), sales stood at ₹574 crore, reflecting a 16% decline from ₹684 crore in 9M-25. Other income saw a 10% increase in Q3-26 to ₹11 crore and a significant 62% rise in 9M-26 to ₹42 crore.
Operating expenses such as Cost of Goods Sold (COGS), Employee Expenses, and Other Expenses were reported. EBITDA for Q3-26 decreased by 65% to ₹13 crore from ₹37 crore in Q3-25. For the 9M-26 period, EBITDA fell by 50% to ₹58 crore from ₹115 crore in 9M-25.
The company reported a Profit Before Tax (PBT) and Profit After Tax (PAT) of -₹6 crore for Q3-26, a notable decrease from ₹24 crore in Q3-25. For the nine-month period, PBT & PAT stood at ₹15 crore, down from ₹78 crore in the prior year.
The investor presentation, which includes these financials, was made available on the company's website and was submitted to the National Stock Exchange of India Limited and BSE Limited on February 11, 2026. This follows an earlier intimation regarding an Analysts/Investors Earning Call scheduled for February 12, 2026, at 04:30 P.M. (IST).
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.